View Financial HealthGenomtec 배당 및 자사주 매입배당 기준 점검 0/6Genomtec 배당금을 지급한 기록이 없습니다.핵심 정보n/a배당 수익률-14.0%자사주 매입 수익률총 주주 수익률-14.0%미래 배당 수익률n/a배당 성장률n/a다음 배당 지급일n/a배당락일n/a주당 배당금n/a배당 성향n/a최근 배당 및 자사주 매입 업데이트업데이트 없음모든 업데이트 보기Recent updatesNew Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 1.1% per year over the past 5 years. Revenue is less than US$1m (zł15k revenue, or US$4.2k). Minor Risk Market cap is less than US$100m (zł86.8m market cap, or US$24.5m).New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.2% per year over the past 5 years. Revenue is less than US$1m (zł11k revenue, or US$3.0k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (zł69.2m market cap, or US$18.8m).Reported Earnings • Oct 05Second quarter 2025 earnings released: zł0.22 loss per share (vs zł0.23 loss in 2Q 2024)Second quarter 2025 results: zł0.22 loss per share (improved from zł0.23 loss in 2Q 2024). Net loss: zł3.35m (flat on 2Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 11% per year.공시 • Aug 25Genomtec S.A. to Report First Half, 2025 Results on Sep 29, 2025Genomtec S.A. announced that they will report first half, 2025 results on Sep 29, 2025New Risk • May 18New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł9.7m free cash flow). Earnings have declined by 0.2% per year over the past 5 years. Revenue is less than US$1m (zł1.0k revenue, or US$261). Minor Risk Market cap is less than US$100m (zł98.1m market cap, or US$25.6m).공시 • May 12Genomtec S.A., Annual General Meeting, Jun 05, 2025Genomtec S.A., Annual General Meeting, Jun 05, 2025.Reported Earnings • Dec 01Third quarter 2024 earnings released: zł0.25 loss per share (vs zł0.23 loss in 3Q 2023)Third quarter 2024 results: zł0.25 loss per share (further deteriorated from zł0.23 loss in 3Q 2023). Net loss: zł3.29m (loss widened 21% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.Reported Earnings • Oct 02Second quarter 2024 earnings released: zł0.23 loss per share (vs zł0.15 loss in 2Q 2023)Second quarter 2024 results: zł0.23 loss per share (further deteriorated from zł0.15 loss in 2Q 2023). Net loss: zł3.38m (loss widened 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.New Risk • Sep 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.0m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (8.7% increase in shares outstanding). Market cap is less than US$100m (zł106.6m market cap, or US$27.9m).공시 • May 31Genomtec S.A., Annual General Meeting, Jun 25, 2024Genomtec S.A., Annual General Meeting, Jun 25, 2024.New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 56% over the past year. Revenue is less than US$1m (zł19k revenue, or US$4.7k). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (zł156.7m market cap, or US$38.7m).공시 • Jan 28+ 3 more updatesGenomtec S.A. to Report First Half, 2024 Results on Sep 27, 2024Genomtec S.A. announced that they will report first half, 2024 results on Sep 27, 2024New Risk • Nov 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 59% over the past year. Revenue is less than US$1m (zł18k revenue, or US$4.5k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł132.4m market cap, or US$33.3m).New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Revenue has declined by 63% over the past year. Revenue is less than US$1m (zł24k revenue, or US$5.8k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-zł10m). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł140.4m market cap, or US$33.8m).Reported Earnings • Jun 02First quarter 2023 earnings released: zł0.20 loss per share (vs zł0.088 loss in 1Q 2022)First quarter 2023 results: zł0.20 loss per share (further deteriorated from zł0.088 loss in 1Q 2022). Net loss: zł2.08m (loss widened 191% from 1Q 2022).공시 • Jun 02Genomtec S.A., Annual General Meeting, Jun 27, 2023Genomtec S.A., Annual General Meeting, Jun 27, 2023, at 13:30 Central European Standard Time.분석 기사 • May 09Is Genomtec (WSE:GMT) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...공시 • Feb 03+ 1 more updateGenomtec S.A. to Report Q2, 2023 Results on Aug 11, 2023Genomtec S.A. announced that they will report Q2, 2023 results on Aug 11, 2023공시 • Mar 19+ 3 more updatesGenomtec S.A. to Report Fiscal Year 2020 Results on May 27, 2021Genomtec S.A. announced that they will report fiscal year 2020 results on May 27, 2021지급의 안정성과 성장배당 데이터 가져오는 중안정적인 배당: 과거에 GMT 의 주당 배당금이 안정적이었는지 판단하기에는 데이터가 부족합니다.배당금 증가: GMT 의 배당금 지급이 증가했는지 판단하기에는 데이터가 부족합니다.배당 수익률 vs 시장Genomtec 배당 수익률 vs 시장GMT의 배당 수익률은 시장과 어떻게 비교되나요?구분배당 수익률회사 (GMT)n/a시장 하위 25% (PL)2.8%시장 상위 25% (PL)7.1%업계 평균 (Biotechs)2.2%분석가 예측 (GMT) (최대 3년)n/a주목할만한 배당금: 회사가 최근 지급을 보고하지 않았기 때문에 하위 25%의 배당금 지급자에 대해 GMT 의 배당 수익률을 평가할 수 없습니다.고배당: 회사가 최근 지급을 보고하지 않았기 때문에 배당금 지급자의 상위 25%에 대해 GMT 의 배당 수익률을 평가할 수 없습니다.주주 대상 이익 배당수익 보장: 배당금 지급이 수익으로 충당되는지 확인하기 위해 GMT 의 지급 비율을 계산하기에는 데이터가 부족합니다.주주 현금 배당현금 흐름 범위: GMT 에서 지급을 보고하지 않았기 때문에 배당 지속 가능성을 계산할 수 없습니다.높은 배당을 제공하는 우량 기업 찾기7D1Y7D1Y7D1YPL 시장에서 배당이 강한 기업.View Management기업 분석 및 재무 데이터 상태데이터최종 업데이트 (UTC 시간)기업 분석2026/05/31 13:59종가2026/05/29 00:00수익2025/09/30연간 수익2024/12/31데이터 소스당사의 기업 분석에 사용되는 데이터는 S&P Global Market Intelligence LLC에서 제공됩니다. 아래 데이터는 이 보고서를 생성하기 위해 분석 모델에서 사용됩니다. 데이터는 정규화되므로 소스가 제공된 후 지연이 발생할 수 있습니다.패키지데이터기간미국 소스 예시 *기업 재무제표10년손익계산서현금흐름표대차대조표SEC 양식 10-KSEC 양식 10-Q분석가 컨센서스 추정치+3년재무 예측분석가 목표주가분석가 리서치 보고서Blue Matrix시장 가격30년주가배당, 분할 및 기타 조치ICE 시장 데이터SEC 양식 S-1지분 구조10년주요 주주내부자 거래SEC 양식 4SEC 양식 13D경영진10년리더십 팀이사회SEC 양식 10-KSEC 양식 DEF 14A주요 개발10년회사 공시SEC 양식 8-K* 미국 증권에 대한 예시이며, 비(非)미국 증권에는 해당 국가의 규제 서식 및 자료원을 사용합니다.별도로 명시되지 않는 한 모든 재무 데이터는 연간 기간을 기준으로 하지만 분기별로 업데이트됩니다. 이를 TTM(최근 12개월) 또는 LTM(지난 12개월) 데이터라고 합니다. 자세히 알아보기.분석 모델 및 스노우플레이크이 보고서를 생성하는 데 사용된 분석 모델에 대한 자세한 내용은 당사의 Github 페이지에서 확인하실 수 있습니다. 또한 보고서 활용 방법에 대한 가이드와 YouTube 튜토리얼도 제공합니다.Simply Wall St 분석 모델을 설계하고 구축한 세계적 수준의 팀에 대해 알아보세요.산업 및 섹터 지표산업 및 섹터 지표는 Simply Wall St가 6시간마다 계산하며, 프로세스에 대한 자세한 내용은 Github에서 확인할 수 있습니다.분석가 소스Genomtec S.A.는 0명의 분석가가 다루고 있습니다. 이 중 0명의 분석가가 우리 보고서에 입력 데이터로 사용되는 매출 또는 수익 추정치를 제출했습니다. 분석가의 제출 자료는 하루 종일 업데이트됩니다.
New Risk • Jan 26New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 11% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (11% average weekly change). Earnings have declined by 1.1% per year over the past 5 years. Revenue is less than US$1m (zł15k revenue, or US$4.2k). Minor Risk Market cap is less than US$100m (zł86.8m market cap, or US$24.5m).
New Risk • Nov 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.3% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Earnings have declined by 1.2% per year over the past 5 years. Revenue is less than US$1m (zł11k revenue, or US$3.0k). Minor Risks Share price has been volatile over the past 3 months (6.3% average weekly change). Market cap is less than US$100m (zł69.2m market cap, or US$18.8m).
Reported Earnings • Oct 05Second quarter 2025 earnings released: zł0.22 loss per share (vs zł0.23 loss in 2Q 2024)Second quarter 2025 results: zł0.22 loss per share (improved from zł0.23 loss in 2Q 2024). Net loss: zł3.35m (flat on 2Q 2024). Over the last 3 years on average, earnings per share has increased by 12% per year whereas the company’s share price has increased by 11% per year.
공시 • Aug 25Genomtec S.A. to Report First Half, 2025 Results on Sep 29, 2025Genomtec S.A. announced that they will report first half, 2025 results on Sep 29, 2025
New Risk • May 18New major risk - Revenue and earnings growthEarnings have declined by 0.2% per year over the past 5 years. This is considered a major risk. Ultimately, shareholders want to see a good return on their investment and that generally comes from sharing in the company's profits. If profits are declining over an extended period, then in most cases the share price will decline over time unless the company can turn around its fortunes. A trend of falling earnings can be very difficult to turn around. If the company is well already established it may also be a sign the company has matured and is in decline. In addition, if the company pays dividends it will also likely need to reduce or cut them, striking a dual blow to total shareholder returns. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł9.7m free cash flow). Earnings have declined by 0.2% per year over the past 5 years. Revenue is less than US$1m (zł1.0k revenue, or US$261). Minor Risk Market cap is less than US$100m (zł98.1m market cap, or US$25.6m).
공시 • May 12Genomtec S.A., Annual General Meeting, Jun 05, 2025Genomtec S.A., Annual General Meeting, Jun 05, 2025.
Reported Earnings • Dec 01Third quarter 2024 earnings released: zł0.25 loss per share (vs zł0.23 loss in 3Q 2023)Third quarter 2024 results: zł0.25 loss per share (further deteriorated from zł0.23 loss in 3Q 2023). Net loss: zł3.29m (loss widened 21% from 3Q 2023). Over the last 3 years on average, earnings per share has increased by 12% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
Reported Earnings • Oct 02Second quarter 2024 earnings released: zł0.23 loss per share (vs zł0.15 loss in 2Q 2023)Second quarter 2024 results: zł0.23 loss per share (further deteriorated from zł0.15 loss in 2Q 2023). Net loss: zł3.38m (loss widened 71% from 2Q 2023). Over the last 3 years on average, earnings per share has increased by 17% per year but the company’s share price has fallen by 10% per year, which means it is significantly lagging earnings.
New Risk • Sep 20New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 7.7% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł6.0m free cash flow). Revenue is less than US$1m. Minor Risks Share price has been volatile over the past 3 months (7.7% average weekly change). Shareholders have been diluted in the past year (8.7% increase in shares outstanding). Market cap is less than US$100m (zł106.6m market cap, or US$27.9m).
공시 • May 31Genomtec S.A., Annual General Meeting, Jun 25, 2024Genomtec S.A., Annual General Meeting, Jun 25, 2024.
New Risk • Apr 22New minor risk - Share price stabilityThe company's share price has been volatile over the past 3 months. It is more volatile than 75% of Polish stocks, typically moving 6.8% a week. This is considered a minor risk. Share price volatility indicates the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. It also increases the risk of potential losses in the short term as the stock tends to have larger drops in price more frequently than other stocks. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 56% over the past year. Revenue is less than US$1m (zł19k revenue, or US$4.7k). Minor Risks Share price has been volatile over the past 3 months (6.8% average weekly change). Shareholders have been diluted in the past year (21% increase in shares outstanding). Market cap is less than US$100m (zł156.7m market cap, or US$38.7m).
공시 • Jan 28+ 3 more updatesGenomtec S.A. to Report First Half, 2024 Results on Sep 27, 2024Genomtec S.A. announced that they will report first half, 2024 results on Sep 27, 2024
New Risk • Nov 30New major risk - Financial positionThe company has less than a year of cash runway based on its current free cash flow trend. Free cash flow: -zł11m This is considered a major risk. With less than a year's worth of cash, the company will need to raise capital or take on debt unless its cash flows improve. This would dilute existing shareholders or increase balance sheet risk. Currently, the following risks have been identified for the company: Major Risks Less than 1 year of cash runway based on free cash flow trend (-zł11m free cash flow). Revenue has declined by 59% over the past year. Revenue is less than US$1m (zł18k revenue, or US$4.5k). Minor Risks Share price has been volatile over the past 3 months (9.2% average weekly change). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł132.4m market cap, or US$33.3m).
New Risk • Nov 05New major risk - Share price stabilityThe company's share price has been highly volatile over the past 3 months. It is more volatile than 90% of Polish stocks, typically moving 9.2% a week. This is considered a major risk. Share price volatility increases the risk of potential losses in the short-term as the stock tends to have larger drops in price more frequently than other stocks. It may also indicate the stock is highly sensitive to market conditions or economic conditions rather than being sensitive to its own business performance, which may also be inconsistent. Currently, the following risks have been identified for the company: Major Risks Share price has been highly volatile over the past 3 months (9.2% average weekly change). Revenue has declined by 63% over the past year. Revenue is less than US$1m (zł24k revenue, or US$5.8k). Minor Risks Less than 1 year of cash runway based on current free cash flow (-zł10m). Shareholders have been diluted in the past year (31% increase in shares outstanding). Market cap is less than US$100m (zł140.4m market cap, or US$33.8m).
Reported Earnings • Jun 02First quarter 2023 earnings released: zł0.20 loss per share (vs zł0.088 loss in 1Q 2022)First quarter 2023 results: zł0.20 loss per share (further deteriorated from zł0.088 loss in 1Q 2022). Net loss: zł2.08m (loss widened 191% from 1Q 2022).
공시 • Jun 02Genomtec S.A., Annual General Meeting, Jun 27, 2023Genomtec S.A., Annual General Meeting, Jun 27, 2023, at 13:30 Central European Standard Time.
분석 기사 • May 09Is Genomtec (WSE:GMT) In A Good Position To Deliver On Growth Plans?Just because a business does not make any money, does not mean that the stock will go down. For example, biotech and...
공시 • Feb 03+ 1 more updateGenomtec S.A. to Report Q2, 2023 Results on Aug 11, 2023Genomtec S.A. announced that they will report Q2, 2023 results on Aug 11, 2023
공시 • Mar 19+ 3 more updatesGenomtec S.A. to Report Fiscal Year 2020 Results on May 27, 2021Genomtec S.A. announced that they will report fiscal year 2020 results on May 27, 2021